Skip to main content
. 2009 Oct 27;101(2):433–439. doi: 10.1111/j.1349-7006.2009.01416.x

Table 5.

 Clinical outcomes

Peptide
0.5 mg 1.0 mg 2.0 mg
(n = 6) (n = 6) (n = 6)
Injection times of peptide† 8 (4–12) 8 (5–11) 8 (4–34)
Clinical outcome
 Antitumor effect
 PR/SD/PD 0/4/2 0/4/2 1/3/2
 Progression‐free survival (days)† 102 (28–148) 135 (60–675) 131 (31–589)
 Overall survival (days)† 233 (102–334) 207 (135–675) 344 (109–614)

†Median (range). PD, progressive disease; PR, partial response; SD, stable disease.